Advanced Research Projects Agency for Health (ARPA-H)

Notify Limited Submissions if you plan to submit a full proposal, include the topic area and lab you plan to submit on behalf of (you must have submitted a solution summary) // Limit: One full proposal (TA1 or TA2) per lab. 

Limiting Language 
Participation in multiple proposals – Only a small fraction of solution summaries are expected to be encouraged for full proposal submissions. At the solution summary stage, proposing entities may submit separate solution summaries for TA1 and TA2 as the prime. However, at the full proposal stage, proposing entities may only submit one full proposal (either TA1 or TA2) as the prime. Proposing entities may be part of multiple full proposal submissions as subcontractors. In this context a ‘proposing entity’ is an academic lab, small business, or unit of a large business. Different labs with different PIs from the same academic institution are considered separate proposing entities.

Introduction
A growing body of evidence suggests that micro- and nano-plastics (MNPs) harm human health. The Systematic Targeting Of MicroPlastics (STOMP) program seeks to better quantify MNPs in humans; understand the mechanisms of MNP deposition; and, ultimately, improve human health by developing means to limit uptake and remove MNPs from the body.

No Applicants  // Limit: 1 // Tickets Available: 1 

The APECx program aims to create a toolkit to enable accurate chimeric and broadly efficacious vaccine Ag discovery through predictive modeling, high-throughput functional experimentation, and protein engineering. To fundamentally transform the vaccine research and development (R&D) sector, APECx will develop an innovative viral Ag prediction pipeline for broad efficacy by combining expedited experimental protein structure and function determination with high-throughput Ag screening. This will be enhanced with structural and functional prediction and protein modeling algorithms. Product developers will contribute to modeling tool evaluation from the start of the program to ensure discoveries satisfy the translational requirements. The combined effort of all the teams will create a toolkit that will enable the U.S. to achieve genus-level vaccine goals and prevent multiple viral diseases, including those responsible for cancer, acute disease, and chronic illness across the country and the world.